Navigation Links
Anesiva Grants Specific-Use License of Its Needle-Free Drug Delivery Technology to Particle Therapeutics for Diabetes Drug
Date:8/30/2007

License Exemplifies Broad Applicability of Anesiva's Needle-Free Technology

SOUTH SAN FRANCISCO, Calif., and OXFORD, England, Aug. 30 /PRNewswire-FirstCall/ -- Anesiva, Inc. (Nasdaq: ANSV) and Particle Therapeutics Limited today announced that they have entered into an agreement granting Particle Therapeutics a specific-use license to incorporate Anesiva's drug delivery technology into its needle-free, intradermal delivery system for glucagon, a hormone commonly used for the treatment of hypoglycemia associated with Type 1 and Type 2 diabetes.

"This agreement exemplifies the potential of our technology to transform the delivery of proteins, peptides and small molecules in a clinically meaningful way that is also safer, more comfortable and more convenient," said John P. McLaughlin, chief executive officer of Anesiva. "We intend to seek other opportunities for licensing this important platform technology."

"Patients experiencing a hypoglycemic condition may lose consciousness, and if not treated quickly, can suffer short and long-term cerebral damage," remarked Fred Cornhill, Director of Particle Therapeutics. "Current methods of treating diabetic hypoglycemia require the mixing of glucagon powder with a sterile saline solution, followed by needle injection. At present, an estimated 1-1.5 million kits with glucagon powder are sold annually in the U.S. and Europe. Those with Type 1 diabetes typically have at least one to eight such events per year, requiring intervention of another person or summoning of medical assistance. Type 2, insulin dependent diabetes patients have fewer incidents, but, with lower glycemic targets, the incidence of hypoglycemia, requiring third party intervention is increasing. Particle Therapeutics' needle-free device provides a system that can be used quickly by those without special training and without the problems associated with needles."

Under the terms of the license agreement, Anesiva will receive an undisclosed up-front payment, along with milestone payments for certain key clinical and regulatory achievements, royalties on future sales, as well as royalties on revenues from any future sub-licensing of the technology by Particle Therapeutics.

About Anesiva's Drug Delivery Technology

Anesiva owns intellectual property covering the delivery of solid particles of proteins, peptides and small molecules (other than vaccines) into the skin at high velocity by pressurized gases. The technology aims to provide subcutaneous and systemic delivery of drugs without the pain and inconvenience associated with injections and needles. With Anesiva's drug delivery technology, patients may benefit from better control of their disease, reduced dosing schedules, and less pain compared to the administration of drugs with needles. Anesiva is utilizing this technology in its recently FDA-approved product Zingo(TM) (lidocaine hydrochloride monohydrate) powder intradermal injection system, 0.5 mg., for the rapid needle-free local delivery of lidocaine to reduce pain associated with venous access procedures.

About Anesiva and its Diverse Portfolio of Pain Products

Anesiva, Inc. is a late-stage biopharmaceutical company that seeks to be the leader in the development and commercialization of novel therapeutic treatments for pain. The company has one approved product and one drug candidate in development for multiple pain-related indications. On August 16, 2007, the FDA approved Anesiva's first product, Zingo. The second product in the portfolio, Adlea(TM) (formerly 4975), has been shown to reduce pain after only a single administration for weeks to months in multiple settings in numerous mid-stage clinical trials for site-specific, moderate-to-severe pain. Anesiva is based in South San Francisco, CA. For more information about Anesiva's leadership in the development of products for pain management, and an overview of the clinical challenges being addressed by its product candidates, go to http://www.anesiva.com.

About Particle Therapeutics Limited

Particle Therapeutics, a spin out company of the University of Oxford, is a privately-held, UK-based company dedicated to the development, testing and commercialization of needle-free injection of glucagon in the diabetic patient with severe hypoglycemia. Other applications of Particle Therapeutics' technology may include the delivery of insulin in a selected group of patients with diabetes and other conditions. For more information on Particle Therapeutics go to http://www.particletherapeutics.com

Anesiva Forward Looking Statements

This press release includes "forward-looking statements" within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. Words such as "expect," "estimate," "project," "budget," "forecast," "anticipate," "intend," "plan," "may," "will," "could," "should," "believes," "predicts," "potential," "continue," and similar expressions are intended to identify such forward-looking statements. Forward-looking statements in this press release include matters that involve known and unknown risks, uncertainties and other factors that may cause actual results, levels of activity, performance or achievements to differ materially from results expressed or implied by this press release. Such risk factors include, among others: the timing and results of our clinical trials, whether Anesiva will succeed in licensing its needle-free drug technology technology for other uses; whether Anesiva can commercially release new products successfully and the degree to which these products gain market acceptance. Actual results may differ materially from those contained in the forward-looking statements in this press release. Additional information concerning these and other risk factors is contained in Anesiva's quarterly report on Form 10-Q for the quarter ended June 30, 2007.

Anesiva undertakes no obligation and does not intend to update these forward-looking statements to reflect events or circumstances occurring after this press release. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. All forward-looking statements are qualified in their entirety by this cautionary statement.


'/>"/>
SOURCE Anesiva, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. State to offer $850K in high-tech training grants
2. Grants worth $800,000 help BellBrook Labs develop products
3. Venture-backed firms could become eligible for federal SBIR grants
4. Mithridion wins grants for Alzheimers research
5. NASDAQ grants Merge more time for compliance
6. Morgridge seed grants attract over 220 proposals
7. Medical College researchers win federal grants
8. NSF grants bolster integrative graduate study at UW-Madison
9. Three state businesses receive technology grants
10. SBC Foundation awards technology grants in Wisconsin
11. Visonex plans to expand with state grants, loan
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/9/2017)... , Oct. 9, 2017  BioTech Holdings ... mechanism by which its ProCell stem cell therapy ... limb ischemia.  The Company, demonstrated that treatment with ... of limbs saved as compared to standard bone ... molecule HGF resulted in reduction of therapeutic effect.  ...
(Date:10/9/2017)... Charlotte, N.C. (PRWEB) , ... October 09, 2017 , ... ... Purple announced Dr. Christopher Stubbs, a professor in Harvard University’s Departments of Physics and ... Dr. Stubbs was a member of the winning team for the 2015 Breakthrough Prize ...
(Date:10/9/2017)... Antonio, Texas (PRWEB) , ... ... ... new study published on October 5, 2017, in the medical journal, Epilepsia, ... equivalence with the gold standard, video EEG, in detecting generalized tonic-clonic seizures ...
(Date:10/7/2017)... ... October 06, 2017 , ... ... its ProxiMeta™ Hi-C metagenome deconvolution product, featuring the first commercially available Hi-C ... software to perform Hi-C metagenome deconvolution using their own facilities, supplementing the ...
Breaking Biology Technology:
(Date:4/11/2017)... , Apr. 11, 2017 Research and ... Market 2017-2021" report to their offering. ... The global eye tracking market to grow at a ... report, Global Eye Tracking Market 2017-2021, has been prepared based on ... covers the market landscape and its growth prospects over the coming ...
(Date:4/5/2017)... April 5, 2017 Today HYPR Corp. ... the server component of the HYPR platform is officially ... the end-to-end security architecture that empowers biometric authentication across ... has already secured over 15 million users across the ... of connected home product suites and physical access represent ...
(Date:3/30/2017)... KONG , March 30, 2017 The ... a system for three-dimensional (3D) fingerprint identification by adopting ground breaking ... into a new realm of speed and accuracy for use in ... at an affordable cost. ... ...
Breaking Biology News(10 mins):